RBN-2397

RBN-2397 · Ribon Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RBN-2397, covering 2023-07-03 to 2023-07-03. Get the full timeline:

Most recent: Clinical Trial Update: RBN-2397 in Combination With Pembrolizumab in Patients With SCCL [Phase 1, Phase 2]